Neural biomarkers of risk for psychosis
Loading...
Links to Files
Permanent Link
Collections
Author/Creator
Author/Creator ORCID
Date
2015-01-01
Department
Psychology
Program
Psychology
Citation of Original Publication
Rights
This item may be protected under Title 17 of the U.S. Copyright Law. It is made available by UMBC for non-commercial research and education. For permission to publish or reproduce, please see http://aok.lib.umbc.edu/specoll/repro.php or contact Special Collections at speccoll(at)umbc.edu
Distribution Rights granted to UMBC by the author.
Distribution Rights granted to UMBC by the author.
Subjects
Abstract
Schizophrenia is a potentially debilitating mental disorder which is usually preceded by one to two years of attenuated psychotic symptoms. The identification of individuals at psychosis-risk has relied on self-report and interview measures, which have limited specificity. Early identification could benefit from the discovery of biomarkers that may add accuracy of identification when used in conjunction with the self-report measures. Proton Magnetic Resonance Spectroscopy is an imaging technique used to quantify brain metabolites. Development of psychosis may be associated with metabolite concentration changes that reflect an alteration in glutamatergic mechanisms. Elevated glutamate levels have been observed in the striatum of individuals at psychosis-risk and individuals in their first episode of schizophrenia as compared to healthy controls. The current study explored glutamatergic metabolite concentrations in the striatal and cingulate gyri as potential biomarkers to aid in the understanding of psychosis-risk symptoms.